{"id":"NCT00607373","sponsor":"Kastle Therapeutics, LLC","briefTitle":"Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2008-02-05","resultsPosted":"2013-03-21","lastUpdate":"2016-09-09"},"enrollment":51,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lipid Metabolism, Inborn Errors","Hypercholesterolemia, Autosomal Dominant","Hyperlipidemias","Metabolic Diseases","Hyperlipoproteinemia Type II","Metabolism, Inborn Errors","Genetic Diseases, Inborn","Infant, Newborn, Diseases","Metabolic Disorder","Congenital Abnormalities","Hypercholesterolemia","Hyperlipoproteinemias","Dyslipidemias","Lipid Metabolism Disorders"],"interventions":[{"type":"DRUG","name":"mipomersen","otherNames":["ISIS 301012","mipomersen sodium","Kynamroâ„¢"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Mipomersen","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of mipomersen (ISIS 301012) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy.\n\nThis study consisted of a 26-week treatment period and a 24-week post-treatment follow-up period. Following treatment and Week 28 evaluations, participants could elect to enroll in an open-label extension study (301012-CS6; NCT00694109). Participants who were not eligible or elected not to enroll in the open-label extension study or who discontinued during the 28-week treatment period were followed in this study for 24 weeks from administration of the last dose of study drug.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point","timeFrame":"Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET) up to week 28","effectByArm":[{"arm":"Placebo","deltaMin":-3.31,"sd":17.06},{"arm":"Mipomersen","deltaMin":-24.66,"sd":19.85}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":10,"countries":["United States","Brazil","Canada","Singapore","South Africa","Taiwan","United Kingdom"]},"refs":{"pmids":["27578134","25614280","20227758"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":17},"commonTop":["Injection site erythema","Injection site haematoma","Injection site pain","Injection site pruritus","Injection site discolouration"]}}